Sato Yuta, Kudo Shin-Ei, Ichimasa Katsuro, Matsudaira Shingo, Kouyama Yuta, Kato Kazuki, Baba Toshiyuki, Wakamura Kunihiko, Hayashi Takemasa, Kudo Toyoki, Ogata Noriyuki, Mori Yuichi, Misawa Masashi, Toyoshima Naoya, Ishigaki Tomoyuki, Yagawa Yusuke, Nakamura Hiroki, Sakurai Tatsuya, Shakuo Yukiko, Suzuki Kenichi, Kudo Yui, Hamatani Shigeharu, Ishida Fumio, Miyachi Hideyuki
Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama 224-8503, Japan.
Endoscopic Division, Kudo Clinic, Akita 010-0001, Japan.
Oncol Lett. 2018 Dec;16(6):7264-7270. doi: 10.3892/ol.2018.9527. Epub 2018 Sep 28.
With recent advances in endoscopic treatment, many T1 colorectal carcinomas (CRCs) are resected endoscopically with a negative margin. However, some lesions exhibit skip lymphovascular invasion (SLVI), which is defined as the discontinuous foci of the tumor cells within the colon wall. The aim of the present study was to reveal the clinicopathological features of T1 CRCs with SLVI and validate the Japanese guidelines regarding SLVI. A total of 741 patients with T1 CRCs that were resected surgically between April 2001 and October 2016 in our hospital were divided into two groups: With SLVI and without SLVI. Clinicopathological features compared between the two groups were patient's gender, age, tumor size, location, morphology, lymphovascular invasion, tumor differentiation, tumor budding and lymph node metastasis. The incidence of T1 CRCs with SLVI was 0.9% (7/741). All cases with SLVI were found in the sigmoid colon or rectum. T1 CRCs with SLVI showed significantly higher rates of lymphovascular invasion than those without SLVI (P<0.01). In conclusion, lymphovascular invasion was a significant risk factor for SLVI in T1 CRCs, and for which surgical colectomy was necessary. The Japanese guidelines are appropriate regarding SLVI. Registered in the University Hospital Medical Network Clinical Trials Registry (UMIN000027097).
随着内镜治疗的最新进展,许多T1期结直肠癌(CRC)通过内镜切除且切缘阴性。然而,一些病变表现出跳跃性淋巴管侵犯(SLVI),其定义为结肠壁内肿瘤细胞的不连续病灶。本研究的目的是揭示具有SLVI的T1期CRC的临床病理特征,并验证日本关于SLVI的指南。2001年4月至2016年10月在我院接受手术切除的741例T1期CRC患者被分为两组:有SLVI组和无SLVI组。两组之间比较的临床病理特征包括患者的性别、年龄、肿瘤大小、位置、形态、淋巴管侵犯、肿瘤分化、肿瘤芽生和淋巴结转移。具有SLVI的T1期CRC的发生率为0.9%(7/741)。所有SLVI病例均位于乙状结肠或直肠。具有SLVI的T1期CRC的淋巴管侵犯率显著高于无SLVI者(P<0.01)。总之,淋巴管侵犯是T1期CRC中SLVI的一个重要危险因素,因此需要进行手术结肠切除术。日本关于SLVI的指南是合适的。注册于大学医院医学网络临床试验注册中心(UMIN000027097)。